Australia cuts down public health bill by investing in new medicines under PBS - Report

24 November 2015
australia-big

Investing in new medicines helps cut down other public health expenditure in Australia, according to a new report from American economist Professor Frank Lichtenberg.

The report indicates the benefits of investing in the Pharmaceutical Benefits Scheme (PBS) by the Australian government.

Trade group Medicines Australia chief executive Tim James said: “This comprehensive study shows that taxpayers and patients are getting value for money from government investment in the PBS. The report clearly demonstrates that the PBS is highly cost effective and also reduces health expenditure across our hospitals.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical